There are 2934 resources available
Proffered Paper 1 – Genitourinary tumours, non-prostate - Invited Discussant LBA54 and LBA55
Presenter: Ignacio Duran Martinez
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Slides
Webcast
1056 - Primary 2-year (yr) results of a phase 2, multicenter, randomized, open-label trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma
Presenter: Reinhard Dummer
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
2898 - Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase 2 trial (IMMUNED)
Presenter: Dirk Schadendorf
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Proffered Paper – Melanoma and other skin tumours - Invited Discussant LBA66, LBA67 and 1310O
Presenter: Bartosz Chmielowski
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Slides
Webcast
2545 - 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma
Presenter: James Larkin
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1691 - PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
Presenter: Benedetta Pellegrino
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast
2339 - Interferon ɣ (IFN-ɣ) gene signature and tryptophan 2,3-dioxygenase 2 (TDO2) gene expression: a potential predictive composite biomarker for linrodostat mesylate (BMS-986205; indoleamine 2,3-dioxygenase 1 inhibitor [IDO1i]) + nivolumab (NIVO)
Presenter: Jason Luke
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast
2801 - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
3661 - Long-term Outcomes from the Randomized Ph 2 Study of Nivolumab (nivo) or Nivo+Ipilimumab (ipi) in Patients (pts) with Melanoma Brain Metastases (mets): Anti-PD1 Brain Collaboration (ABC)
Presenter: Georgina Long
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
4844 - EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Presenter: Christopher Hoimes
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast